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commons.org/licenses/by/4.0/).1. Preamble
1.1. Need for developing case definitions and guidelines for data
collection, analysis, and presentation for neonatal seizures as an
adverse event following immunization
Seizures are the most common neurological emergency in new-
borns and can be associated with significant mortality and neuro-
developmental disability. Neonatal seizures are a major challenge
for clinicians because of inconspicuous clinical presentation, vari-
able electro-clinical correlation, and poor response to antiseizure
drugs. It is well recognized that fever and infection can trigger sei-
zures in young children and that this risk is enhanced in children
with epilepsy. As immunization may cause a fever, vaccination
can be a non-specific trigger for seizures in children [1]. On the
other hand, children with epilepsy do not appear to be at increased
risk of seizures following immunization [2]. It is unclear whether
vaccination in newborns or maternal vaccination, is associated
with a higher risk of neonatal seizures. However, as maternal
immunization with established vaccines becomes more prevalent
across multiple geographies, and new maternal vaccine candidates
enter late-stage development, it is becoming increasingly impor-
tant to create easily adopted standard definitions for adverse
events potentially associated with these interventions. The
Brighton Collaboration has previously published a case definition
for seizures in children [3] but not for seizures in neonates.
1.1.1. Epidemiology of neonatal seizures
The reported prevalence and incidence of neonatal seizures vary
considerably due to differences in study methodology, especially in
the identification of neonatal seizures, and geographic setting [4,5].
The majority of seizures in neonates present without clinical signs
[6,7] and can be recognized only with cEEG (conventional elec-
troencephalography) monitoring, which has not been used in all
studies. Therefore, the exact incidence of electrographic, clinically
silent neonatal seizures in term and preterm babies is not known
(Tables 1 and 2).
Incidence. The reported incidence of neonatal seizures
worldwide varies from 1.0–4.4 per 1000 livebirths in high-income
countries (USA) [8,9,16], to 5 per 1000 live births in upper middle-
income countries (Iran) [13]. Reports from low- and middle-
income countries are limited, but one study from Kenya reported
an incidence of 39.5 per 1000 live births [15]. Among the preterm
population, incidences vary considerably according to different
methods of diagnosis. Based only on clinical observation the inci-
dence of seizure in preterms has been reported to be 3.9–57.5
per 1000 live births [8,10,17], whereas studies using amplitude-
integrated electroencephalography (aEEG), reveal a seizure burden
up to 48% [11,18,19]. However, it is well recognized that aEEG can
be falsely positive particularly in preterm infants [20]. Studiesusing cEEG in preterms indicate an incidence of 4–9% in high-
income countries (75% of which are electrographic-only seizures)
[21,22].1.1.2. Etiology of neonatal seizures
The etiology of neonatal seizures is heterogeneous, and some-
times unknown, although the majority are due to hypoxia-ische-
mia, stroke or infections in term infants. In preterm infants,
intraventricular hemorrhage is the commonest cause of seizure
[29,30].
The heterogeneity in the etiologic profile of neonatal seizures
across geographies and economic strata is due to two main factors:
differences in obstetric/perinatal care and access to electrodiagnos-
tic techniques leading to differing rates of detection and diagnosis
(Table 2).1.1.3. Timing of onset
The onset of neonatal seizures depends on etiology and is most
common within the first week of life, with 25–55% occurring in the
first 24 h [15,24,31]. Onset is generally later in preterm compared
to term infants [29].1.1.4. Risk factors
Maternal risk factors for neonatal seizures include maternal age
>40 years, nulliparous, diabetes mellitus, chorioamnionitis, trau-
matic delivery, prolonged second stage of labor, fetal distress, pla-
cental abruption, cord prolapse, and uterine rupture[23].
Neonatal risk factors for seizures include the etiologies for sei-
zure listed in Table 2.1.1.5. Outcomes
While a normal neurological outcome after neonatal seizures is
reported in 25–40% of infants [21,32], 15–30% develop cerebral
palsy [32–34]; 30–50% developmental delay [21,32]; and 20–35%
epilepsy [32,33]. The prognosis of neonatal seizures depends on
the underlying etiology. However, there is evidence that seizures
are independently associated with worse outcome [35,36]. Risk
factors identified for poor outcome following neonatal seizures
include prematurity/low birth weight, severity of HIE, high-grade
intraventricular hemorrhage, persistently abnormal EEG back-
ground activity, seizure burden (electrographic seizure burden of
>13 min/h), presence of neonatal status epilepticus (but not recur-
rent seizures), central nervous system infection and cerebral dys-
genesis [4,26,35,37,38]. Death is reported among 7–25% of
neonates with seizures in low-, middle-, and high-income
countries [15,25,32,36], mostly due to the underlying etiology.
Mortality is higher among preterm and low-birthweight neonates
(30–33%) [22,39].
Table 1
Incidence of neonatal seizures.
Area Setting Population Seizure detection Incidence Ref.
USA NICU (1985–89) Term and preterm (n = 16,428) Clinical/EEG (Record review) Overall: 3.5/1000 live births
VLBW: 57.5/1000 live births
LBW: 4.4/1000
NBW: 2.8/1000 live births
HBW: 2.0/1000 live births
[8]
USA NICU (1992–94) Term and preterm (n = 116,048) Clinical (Record review) Overall: 1.8/1000 live births
VLBW: 19/1000 live births
[9]
Canada NICU (1990–95) Term and preterm Clinical/cEEG Overall: 2.5/1000 live births [10]
UK NICU (2007–08) Preterm (<30 weeks) (n = 51) aEEG 22% (aEEG)
4% (clinically)
[11]
India NICU (2011–13) Term and preterm (n = 10724) Clinical 1.6% clinical seizure in first 28 days [12]
Iran NICU (2007–09) Term and preterm (n = 699) Clinical 3.6% of NICU admission 5/1000 live births (extrapolated) [13]
Iran NICU (2008–11) Term and preterm (n = 1112) Clinical 9.1% of NICU admission [14]
Kenya NICU (2003–07) Term and preterm (n = 1600) Clinical 9% of NICU admissions
39.5/1000 live births (extrapolated)
[15]
xLegend: NICU (neonatal intensive care unit), VLBW (<1500 g), LBW (1500–2499 g), NBW (2500–3999 g), HBW (4000 g), cEEG (conventional EEG), aEEG (amplitude-
integrated EEG).
Table 2
Etiology of neonatal seizures and reported relative frequency in high-, middle- and low- income countries.
Etiology High-income countries [8,10,16,23–26] Middle and Low- income countries [12,13,23,24,27–30] Pooled [5,27,28]
Hypoxic-ischemic encephalopathy 38–46% 8–77.9% 12.5–77%
Intracranial hemorrhage 12% 6.9–26% 7–17%
Cerebral infarction 7–18% 12.8% 6–17%
Cerebral malformations 2.9–10% 1.1–5.2% 3–17%
Infections 4–20% 8–60% 0.7–24%
Metabolic
– Hypoglycemia 4–9% 1–16.2% 1–13%
– Electrolytes (Na, K, Ca, Mg) 6% 2.8–14.9% 0.5–43%
– Inborn errors of metabolism 3% 1–2.1% 3–4%
Hyperbilirubinemia/kernicterus N/A 4.6–12% 1%
Maternal drug withdrawal N/A 1.7% 4%
Genetic 3–6% N/A N/A
Unknown 9–14% 2.1% 2%
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Developmental age-specific mechanisms influence the genera-
tion and phenotype of seizures. While there are some limitations
in the use of animal models to study neonatal seizures, conclusions
can be reached with consideration of the species-specific matura-
tion rates in the system of interest [40].
The neonatal period is a time of intense brain development.
While cortical lamination is fully developed in the term infant,
neurite outgrowth and synaptogenesis are continuing and are in
their elementary stages. Brain myelination is immature. These fac-
tors limit the rapid propagation of neonatal seizures and their clin-
ical presentation (with generalized, from onset, tonic-clonic
seizures rarely occurring) [41].
In the neonatal brain, the balance between excitatory versus
inhibitory synapses is tipped in favor of excitation to permit robust
activity-dependent synaptic formation, plasticity, and remodeling.
Glutamate is the major excitatory neurotransmitter in the CNS
with the involvement of AMPA and NMDA receptors and more
expression and function than in the adult brain. For example,
while, in the adult brain, c-amino-butyric acid (GABA) usually
induces membrane hyperpolarization, early in the developing
brain it induces membrane depolarization by causing Cl efflux
rather than influx. The HCN channels, which are members of the
K+ channel super-family and important for maintenance of resting
membrane potential and dendritic excitability, are also develop-
mentally regulated. The immature brain has relatively low expres-
sion of the HCN1 isoform, which serves to reduce dendritic
excitability in the adult brain [40].
Genetic epilepsies with onset in the neonatal period reflect the
structural and physiologic factors that can lead to neonatalseizures. These include ion channel function (e.g. KCNQ2), excita-
tion-inhibition balance (e.g. pyridoxine-dependent epilepsy), brain
development (e.g. ARX) and synaptic function (e.g. STXBP1) [42].
Some of the epilepsy syndromes with neonatal seizures have a
favorable or ‘‘benign” prognosis (self-limiting familial neonatal sei-
zures), however there exist severe epileptic encephalopathies with
a poor outcome (neonatal myoclonic encephalopathy and early
infantile epileptic encephalopathy or Ohtahara syndrome).
1.1.7. Diagnosis of neonatal seizures
The clinical diagnosis of neonatal seizures is challenging
because many neonatal seizures either manifest with subtle clini-
cal signs or remain entirely subclinical despite the presence of
clear electrographic seizure activity on EEG.
Clinical manifestations of neonatal seizures may include focal
motor movements or non-motor signs [79], but manifestations
are usually discreet and are often difficult to distinguish from other
physiologic non-seizure movements such as eye deviation,
automatisms, apnea and limb posturing [43]. Furthermore, numer-
ous studies applying conventional EEG (cEEG) monitoring in
neonatal cohorts have consistently demonstrated that the majority
of neonatal seizures are subclinical [7,44], especially in preterm
infants [45].
The diagnosis of neonatal seizures may be made by cEEG,
amplitude-integrated EEG (aEEG) or by clinical signs alone. Gold-s-
tandard is capturing a seizure on cEEG (ictal EEG) because it pro-
vides the most direct and comprehensive assessment of neuronal
activity. In comparison, aEEG is less accurate because it employs
fewer electrodes over a smaller spatial area and the aEEG display
is filtered and time-compressed making it harder to identify brief
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nel, the median sensitivity for seizure identification is 76% (range:
71–85%), and the median specificity is 85% (range: 39–96%). When
aEEG was used without a real-time EEG channel, the median sen-
sitivity is 39% (range: 25–80), and specificity is 95% (range 50–
100) [46]. On the other hand, when the goal is identifying only
the presence or absence of seizures in a neonate rather than indi-
vidual seizures, the median sensitivity of aEEG with a real-time
EEG channel rises to 85% (range: 70–90%).
Among neonates who present with clinically apparent seizures,
antiseizure drugs commonly suppress clinical activity, but ongoing
electrographic seizures persist, a phenomenon termed uncoupling
[47–50]. Because of this uncoupling, which can also occur sponta-
neously, aEEG or cEEG monitoring is even more essential for the
accurate assessment of response to therapy and seizure burden
[51]. Practitioners should be aware of the limitations of the clinical
assessment in over and under-diagnosing seizures, and aEEG or
cEEG confirmation of clinically-diagnosed seizures should be
sought whenever possible.1.1.8. Differential diagnosis
Early recognition and accurate diagnosis of seizures in the
neonatal period is essential for optimal management. However,
the clinical diagnosis of seizures in neonates is also challenging
because infants may present with abnormal movements that are
non-epileptic but are mistaken for seizures leading to inappropri-
ate treatment and unwarranted prognostic concern [52]. While
the most common non-epileptic movements are generally benign
and associated with a good prognosis, some may be associated
with pathologic conditions. The video-EEG recording of the event
can be very helpful to differentiate seizure from non-epileptic
events. Seizures can coexist with non-epileptic manifestation in
some patients. Table 3 summarizes the characteristics of the most
common non-epileptic manifestation in newborns.1.1.9. Neonatal seizures following maternal or neonatal vaccination
Maternal vaccination. A literature search conducted by the
authors did not identify any reports of seizures among newborns
born to women who received tetanus-diphtheria-acellular pertus-
sis (Tdap), tetanus toxoid, tetanus-diphtheria (Td), seasonal or pan-
demic influenza vaccines, or in randomized controlled trials of
investigational Group B Streptococcus or respiratory syncytial virusTable 3
Differential diagnosis of neonatal seizures.
Syndrome Etiology Description of events
Jitteriness/tremor Physiological, or secondary
(HIE, metabolic, etc.)
Tremors (rhythmical oscillatory
sensitive, diminish with passiv
Benign neonatal
sleep myoclonus
Sudden involuntary jerking wit
tremor, that occur solely durin
Startle disease
(hyperekplexia)
Genetic, autosomal
dominant
Exaggerated startle response m
severe spasms
Paroxysmal
extreme pain
disorder
Genetic, autosomal
dominant
May present with flushing, ton
syncope
Acute bilirubin
encephalopathy
Unconjugated
hyperbilirubinemia
May present with acute neurol
oculogyric movements and dys
Neonatal tetanus Exposure to spores of
Clostridium tetani
Muscle spasms and severe rigid
feeding due to trismus
Autonomic
paroxysms
Episodes of apnea, pallor, flush
tachycardia or hypertension
Sandifer syndrome Gastroesophageal reflux Episodic dystonic posturing wi
hyperextension (opisthotonos)
Tonic posturing Severe hypoxic brain injury Generalized tonic posturing
Other non-epileptic
myoclonus
Benzodiazepine exposure in pr
dependent mothersvaccines. A retrospective cohort study of pertussis among infants
<63 days of age reported no seizures among 34 infants (median
age 45 days) whose mothers received Tdap during pregnancy,
while 14/336 (4%) infants of unvaccinated mothers developed sei-
zures with pertussis infection (relative risk 0.96; 95% CI 0.94–0.98)
[63]. There is currently no evidence of an association between vac-
cination during pregnancy and neonatal seizures.
Neonatal vaccination. In a study of claims in the United States
National Vaccine Injury Compensation Program of seizures and/
or encephalopathy allegedly caused by an immunization among
children younger than two years during 1995–2005, a total of 90
claims (60%) concerned babies between 0 and 6 months of age
but the number of neonates was not reported [64]. In 12 cases
(7.2%) the final diagnostic impression by a pediatric neurologist
was ‘‘infantile seizures”. This article provides no certainty about
a causal effect because it is a summary of individual cases in a lit-
igation setting. Another study found no increase in seizures or
other neurologic events among healthy, full-term neonates who
received hepatitis B vaccination versus controls [65]. In addition,
there were no reports of neonatal seizures after polio or bacille Cal-
mette-Guérin (BCG) vaccination, the vaccinations most commonly
used in the neonatal period [66].1.1.10. Existing definitions for neonatal seizures
Several definitions of neonatal seizures exist (Table 4). Neonatal
seizures are traditionally defined as paroxysmal alterations in neu-
rologic function (including motor, behavior and/or autonomic
function) occurring in the first 28 days after birth of a term neonate
or before 44 weeks of gestational age in a preterm infant [67]. It
should be noted that this purely clinical definition of neonatal sei-
zures is entirely arbitrary, resulting in both over and underestima-
tion of the number of seizures in the newborn [7]. Several studies
have shown the existence of considerable inter-observer variability
among physicians and allied health professionals in the clinical
diagnosis of seizures in the NICU [68]. According to the Interna-
tional League Against Epilepsy (ILAE), an epileptic seizure is
defined as an electro-clinical phenomenon characterized by the
transient occurrence of signs and symptoms due to an abnormal,
excessive or synchronous neuronal activity in the brain [69].
Therefore, the identification of ictal discharges on the EEG (electro-
graphic seizure) should be considered the gold standard for the
accurate diagnosis of neonatal seizures (see Section 1.1.7). A recentPrognosis/outcome Ref.
movements), stimulus
e flexion of extremity
Dependent on cause [53,54]
h a higher amplitude than
g sleep
Excellent [55,56]
ay present with apnea and Stiffness resolves by three years,
exaggerated startle remains
[52,54]
ic spasms, bradycardia, and Paroxysmal episodes of deep
burning pain
[52]
ogic signs such as hypertonia,
tonic posturing
Depending on levels [54,57]
ity may present with poor Mostly fatal [58]
ing, and cyclic periods of [54,59]
th torticollis and severe Usually good [60,61]
Poor [28,62]
eterm infant, infants of opiate Related to underlying cause [54,55]
Table 4
Existing definitions of neonatal seizures.
References [#] Definition of Neonatal seizure
Clancy et al., 1987 [70] An electrographic seizure is defined as a clear ictal event characterized by the appearance of sudden, repetitive, evolving stereotyped
waveforms with a definite beginning, middle, and end; lasting an (arbitrary) minimum ictal duration of 10 s
Volpe, 1989 [71] A seizure is defined clinically as a paroxysmal alteration in neurologic function, i.e., behavioral, motor, and/or autonomic function. Such a
definition includes clinical phenomena that are associated temporally with (surface-recorded) EEG seizure activity and therefore are
clearly epileptic, i.e., related to hypersynchronous electrical discharges that may spare and activate other brain structures. The definition
also includes paroxysmal clinical phenomena that often are not associated temporally with EEG seizure activity; whether any of these
clinical phenomena may also be epileptic (e.g. related to hypersynchronous electrical discharges from subcortical structures and not
detected by surface EEG) is not entirely clear
ILAE, Fisher et al., 2005
[69]*
An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the
brain
Andre et al., 2010 [72] Critical or ictal discharges are abrupt and transient changes in background activity; their duration ranges from 10 s to several minutes
ACNS, Tsuchida et al.,
2013 [73]
An electrographic seizure is a sudden, abnormal EEG event defined by a repetitive and evolving pattern with a minimum 2 mV pp voltage
and duration of at least 10 s. A seizure is always an abnormal pattern and should not be confused with transient background changes, such
as those associated with drowsiness or arousal from sleep. ‘‘Evolving” is defined as an unequivocal evolution in frequency, voltage,
morphology, or location
Legend: ILAE (International League Against Epilepsy); ACNS (American Clinical Neurophysiology Society).
* Not specifically for neonatal seizure
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also recommended the use of EEG for the confirmation of sus-
pected neonatal seizures at all levels of care [27].1.1.11. Classification of neonatal seizures
Neonatal seizures are focal, often subclinical [6] or have discreet
clinical manifestations that are difficult to differentiate frommove-
ments of severely ill newborns [71,74]. Historically, seizure semiol-
ogy in the neonatal period was considered to differ to those of
other ages and therefore specific classification systems for neo-
nates were developed. Some classification systems are based on
direct observation only [71,75–77], whereas others are based on
clinical observation and video EEG [74] (Table 5). However, there
is no universally accepted classification in the neonatal period
and therefore no common language to describe neonatal seizures.
The 2017 ILAE Position Papers on Classification [77,78] are impor-
tant updates on the terminology and etiology of seizures but
specifically do not include neonatal seizures. A Neonatal Seizure
Task Force of the ILAE has proposed a new framework that uses
EEG and clinical seizure semiology to classify seizures in the
neonatal period according to the predominant seizure type (elec-
trographic only, motor, or non-motor) [79]. Motor seizures may
be automatisms, clonic, epileptic spasms, myoclonic, sequential
or tonic and non-motor seizures may be autonomic or behavior
arrest seizures.1.1.12. Need for a harmonized definition of neonatal seizures in the
neonate
There is no uniformly accepted definition of neonatal seizures.
This provides the opportunity to offer a definition that is practical
and useful in the context of neonatal seizures following maternal
and neonatal immunization, as data comparability across trials or
surveillance systems will facilitate data interpretation and theTable 5
Classifications used for neonatal seizures.
Reference [#] Target group (age) EEG diagnost
Volpe, 1973, 1989 [71,80] Neonates No
Mizrahi & Kellaway, 1987 [74] Neonates Yes
ILAE, 1981* [76] >1 month No
ILAE, Fisher et al., 2017* [77] >1 month No
ILAE, Pressler et al. [79] Neonates Yes
Legend: ILAE (International League Against Epilepsy).
* Not specifically for neonatal seizure.assessment of vaccine safety, as well as promote the scientific
understanding of neonatal seizures.1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for neonatal seizures as
an adverse events following immunization
Following the process described in the overview papers [81,82]
as well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Neonatal Seizures Working Group was
formed in 2018 and included members with clinical, academic,
public health, industry backgrounds.
To guide the decision-making for the case definition and guide-
lines, we conducted a literature search using Medline, Embase and
the Cochrane Central Register for English language articles report-
ing on seizures among neonates born to women vaccinated during
pregnancy. In addition, we searched for clinical trials, passive and
active surveillance reports, cohort and case-control studies of
specific vaccines evaluated in pregnancy to capture additional
reports of neonatal seizures and confirm the findings of our pri-
mary literature review. Only English language articles and articles
referring to humans were selected for review. The primary search
identified 82 articles excluding duplications of which 80 were
excluded based on review of the title of abstract. The remaining
two articles were excluded after review of the full text as they
did not provide information regarding neonatal seizures and vac-
cines. A search for adverse events after maternal Tdap vaccination
identified one relevant article that mentioned neonatal seizures.
We extended the search to include reports of neonates with sei-
zure after immunization at birth, following the same methods
described above. A total of 194 articles excluding duplications
were identified. Based on abstract content we selected 12 articles
for complete reading. Articles were excluded mainly because theyic criteria Electrographic seizures Use of ILAE terminology
No No
Yes Partially
No Yes
No Yes
Yes Yes
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infants (e.g. ‘‘infants 0–6 months”) or the specific vaccination
schedule. Finally, only one original article was selected for inclu-
sion in our systematic review [65].
1.3. Rationale for selected decisions about the case definition of
neonatal seizures as an adverse event following immunization
The working group agreed that electrographically documented
seizures with or without clinical manifestations represent the most
accurate concept of neonatal seizures. There are several opera-
tional definitions for electrographic seizures in the newborn.
According to the American Clinical Neurophysiology Society
(ACNS), an electrographic seizure in a newborn is defined as a sud-
den, abnormal EEG event characterized by a rhythmic and evolving
pattern with a minimum 2 mV peak-to-peak voltage and duration
of at least 10 s. ‘‘Evolving” is defined as an unequivocal evolution
in frequency, voltage, morphology, or location [73]. However, the
working group considered at length the operational difficulties of
a purely electrographic definition. The cut-off of 10 s of duration
is arbitrary and does not include shorter clinical seizures e.g. myo-
clonic jerks or spasms. Prolonged EEG monitoring in the NICU on
critically ill term/preterm newborns with multiple hemodynamic
supports may be technically very demanding and may not be easily
available in many centers, even in high-income countries. Another
limiting factor will be the non-availability of adequate and appro-
priately trained personnel with special expertise in the recording
and interpretation of EEG in the neonatal ICU setting.
Amplitude-integrated EEG (aEEG) can be a useful instrument
but less accurate (see Section 1.1.7 for further details).
Clinical diagnosis of neonatal seizures is the least accurate
parameter, although some clinical manifestations, such as focal
clonic seizures or focal tonic seizures, particularly when seizures
are stereotyped and recurrent, are highly indicative of epileptic sei-
zures [68]. In contrast, events with generalized tonic posturing
seen in infants with diffuse severe brain injury are usually of
non-epiletic origin [28].
1.3.1. Related terms of neonatal seizures
Neonatal period: begins at birth and ends at 28 completed days
of life [83].
Gestational age (GA): is a clinical term that applies to the esti-
mated age of the fetus during pregnancy, generally given in weeks
and days from the first day of the last menstrual period. According
to the International Statistical Classification of Diseases and
Related Health Problems (ICD-10) [84], GA is used to classify three
different periods in relation to delivery: preterm births (less than
37 weeks), term births (37–41 weeks) and post-term births
(42 weeks or more). For additional information refer to the prema-
ture birth Case Definition of the Brighton Collaboration Preterm
Birth Working Group [85].
Neonatal seizures: relate to epileptic seizures in the neonatal
period. It includes terms such as neonatal convulsions, neonatal
fits, neonatal epilepsy and neonatal convulsive disorder (the latter
two refer to a disorder with repeated unprovoked epileptic sei-
zures, see below). The preferred term is neonatal seizure.
Epilepsy refers to a disorder with at least two unprovoked (or
reflex) seizures occurring greater than 24 h apart or one unpro-
voked (or reflex) seizure and a probability of further seizures sim-
ilar to the general recurrence risk (at least 60%) after two
unprovoked seizures, occurring over the next 10 years [86].
1.3.2. Focus of Brighton Collaboration case definition
The focus of the working group was to agree on a harmonized
definition of neonatal seizures and the criteria to identify them,
with different levels of diagnostic certainty. This will be useful alsofor the identification of neonatal seizures in the context of vaccina-
tion of mothers during pregnancy or neonatal vaccination.
1.3.3. Formulating a case definition that reflects diagnostic certainty:
weighing specificity versus sensitivity
It needs to be emphasized that the grading of definition levels is
entirely about diagnostic certainty, not the clinical severity of an
event. Thus, a very severe clinical event may appropriately be clas-
sified as possible (level 3) or probable (level 2), rather than definite
(level 1), if it could reasonably be of a non-epileptic etiology.
Detailed information about the severity of the event should addi-
tionally always be recorded, as specified by the data collection
guidelines.
The number of symptoms and/or signs that will be documented
for each case may vary considerably. The case definition has been
formulated such that the level 1 definition is highly specific for
the condition. As maximum specificity normally implies a loss of
sensitivity, two additional diagnostic levels have been included
in the definition, offering a stepwise increase of sensitivity from
level 1 down to level 3, while retaining an acceptable level of speci-
ficity at all levels. In this way, it is hoped that all possible cases of
neonatal seizures can be captured.
1.3.4. Rationale for individual criteria or decision made related to the
case definition
The working group agreed to a definition of neonatal seizures
(see below) and to give different levels of certainty in the diagnosis
(depending on the use of instrumental tools such as cEEG and aEEG
or the sole clinical observation) in order to be effective and appli-
cable in high-, middle- and low-income countries.
Pathology, radiology and laboratory findings are not included in
the case definition, although they can provide important informa-
tion regarding the causes of neonatal seizure.
1.3.5. Influence of treatment on the fulfilment of the case definition
The working group decided against using ‘‘treatment” or ‘‘treat-
ment response” towards the fulfillment of the case definition of
neonatal seizures.
A treatment response or failure is not in itself diagnostic, as less
than 50% of neonatal seizures respond to the first line treatment
(phenobarbital) [27,87,88]. At the same time, many antiseizure
drugs have sedative or central nervous system depressant effects
and may reduce the intensity or frequency of non-epileptic move-
ments. It is only in certain circumstances, such as acute symp-
tomatic seizures due to hypoglycemia or pyridoxine-dependent
seizures, that specific treatments have diagnostic implications.
1.3.6. Timing post maternal immunization
Specific time-frames for the onset of symptoms of neonatal sei-
zures following maternal immunization are not included. No infor-
mation is available regarding the potential relevance of the timing
of maternal immunization and the occurrence of neonatal seizures.
We postulate that a definition designed to be a suitable tool for
testing causal relationships requires ascertainment of the outcome
(e.g. neonatal seizures) independent from the exposure (e.g. mater-
nal immunization). Therefore, to avoid selection bias, a restrictive
time interval frommaternal immunization to onset of neonatal sei-
zures should not be an integral part of such a definition. Instead,
where feasible, details of this interval should be assessed and
reported as described in the data collection guidelines.
Furthermore, neonatal seizures often occur outside the con-
trolled setting of a clinical trial or hospital. In some settings, it
may be impossible to obtain a clear timeline of the event, particu-
larly in low resource and rural settings. To avoid exclusion of such
cases, this Brighton Collaboration case definition avoids setting
Level 1 of diagnostic certainty
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rence of the defined event.1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview, the case definition is accompa-
nied by guidelines which are structured according to the steps of
conducting a clinical trial, i.e. data collection, analysis and presen-
tation. Neither case definition nor guidelines are intended to guide
or establish criteria for management of ill infants, children, or
adults. Both were developed to improve data comparability.1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.2. Case definition of neonatal seizures2
Case definition
A neonatal seizure is defined as a transient electrographic
change in the brain due to an abnormal, excessive or synchronous
neuronal activity either with the occurrence of clinical signs (elec-
tro-clinical) or without them (electrographic-only), in the first
28 days of life in full-term infants. In the preterm infants (born
<37 weeks of gestation), this definition applies up to 44 weeks of
post menstrual age (PMA), considering the pattern of brain
maturation.
Seizures confirmed by conventional EEG (cEEG) with or without
clinical manifestations represent the most accurate concept of
neonatal seizures; cEEG is considered the gold standard for neona-
tal seizure diagnosis (Level 1 – ‘‘definite” diagnosis). Ictal EEG
refers to the epileptiform activity seen during a seizure in contrast
to interictal discharges seen between seizures which are not diag-
nostic in neonates. Concomitant video recording is helpful
although not a necessity and may be replaced by clinical observa-
tion during the EEG to determine a clinical-electrographic
correlation.2 The case definition should be applied when there is no clear alternative diagnosis
for the reported event to account for the combination of symptoms.Amplitude-integrated EEG (aEEG) or cerebral function monitor-
ing can be a useful instrument but is less accurate than cEEG (see
Section 1.1.7). The identification of seizures on the aEEG is consid-
ered a ‘‘probable” diagnosis of neonatal seizure (Level 2a).
As mentioned above, the clinical diagnosis of neonatal seizures
is challenging and without EEG it is difficult to differentiate seizure
from physiological or abnormal, but non-epileptic, movements
(see Section 1.1.8). However, two seizure types are highly indica-
tive of epileptic seizures, specifically focal tonic seizures (focal sus-
tained stiffening/sustained increase in muscle contraction lasting a
few seconds to minutes) or focal clonic (regularly rhythmic jerking,
that involves the samemuscle groups), which are not influenced by
manual restraint [77]. Therefore, these seizure types also can be
considered ‘‘probable seizures” (Level 2b) in the absence of a con-
firmation EEG, if observed by experienced medical personnel (a
history of such events is not considered sufficient). The term ‘‘ex-
perienced medical personnel” refers to who routinely care for neo-
nates and are familiar with the clinical presentation of neonatal
seizures through training or clinical practice. Ideally this is a physi-
cian (not restricted to neonatology or neurology specialists), but in
different settings also other professionals (such as advanced care
provider, nurse, or individual such as midwife, health care worker)
could diagnose ‘‘probable or possible seizures”, depending of their
specific training in neonatal care.
As discussed in Section 1.1.11, neonatal seizure types also
include other motor or non-motor manifestations such as myoclo-
nic jerks, epileptic spasms, automatisms, autonomic changes and
behavioral arrest. Based only on clinical observation (without
EEG confirmation) it is not possible to label these manifestations
as definite neonatal seizures, however, they can be considered
‘‘possible” seizure (Level 3), if observed by experienced medical
personnel (a history of such events is not considered sufficient).
Generalized tonic events and bilateral hypermotor events are usu-
ally non-epileptic.
For further information on clinical manifestations and defini-
tions of seizure types and epilepsy syndromes see https://www.
epilepsydiagnosis.org/index.html.
LEVELS OF CERTAINTY
For All Levels of Diagnostic Certainty
Age 0–28 days in a full-term infant
OR
Postmenstrual age of <44 weeks in a preterm infant (born
<37 weeks of gestation)
Level 2 of diagnostic certainty
Level 3 of diagnostic certainty
Level 4
Level 5
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2sudden, abnormal EEG event characterized by repetitive and
evolving pattern (in frequency, voltage, morphology, or location)
3seizure confirmed with EEG and with clear clinical
manifestation
4seizure confirmed with EEG without clear clinical
manifestation
5regularly rhythmic jerking, that involves the same muscle
groups and not influenced by manual restraint
6focal sustained stiffening/sustained increase in muscle con-
traction lasting a few seconds to minutes and not influenced by
manual restraint
7someone who routinely cares for neonates and is familiar with
the clinical presentation of neonatal seizures through training or
clinical practice. Ideally this is a physician (not restricted to neona-
tology or neurology specialists), but in different settings also other
professionals (such as advanced care provider, nurse, or individual
such as midwife, health care worker) could diagnose ‘‘probable or
possible seizures”, depending of their specific training in neonatal
care
8such as myoclonic, epileptic spasm, automatism, autonomic
changes, behavioral arrest, but non-seizure events cannot be
excluded without EEG [79]3. Guidelines for data collection, analysis and presentation of
neonatal seizures
It was the consensus of the Brighton Collaboration Neonatal Sei-
zures Working Group to recommend the following guidelines to
enable meaningful and standardized collection, analysis, and pre-
sentation of information about neonatal seizures. However, the
implementation of all guidelines might not be possible in all set-
tings. The availability of information may vary depending upon
resources, geographical region, and whether the source of informa-
tion is a prospective clinical trial, a post-marketing surveillance or
epidemiological study, or an individual sporadic report of neonatal
seizures. Also, these guidelines have been developed by this work-
ing group for guidance only and are not to be considered a manda-
tory requirement for data collection, analysis, or presentation.3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on neonatal seizures following maternal immunization
to allow for comparability of data and are recommended as an
addition to data collected for the specific study question and set-
ting. The guidelines are not specifically intended to guide the pri-
mary reporting of neonatal seizures to a surveillance system or
study monitor, but they could potentially be adapted for these pur-
poses. Investigators developing a data collection tool based on
these data collection guidelines also need to refer to the criteria
in the case definition, which are not repeated in these guidelines.
Guidelines numbered below have been developed to address
data elements for the collection of adverse event information as
specified in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use, and the form for report-
ing of drug adverse events by the Council for International
Organizations of Medical Sciences. These data elements include
an identifiable reporter and patient, one or more prior maternal
immunization, and a detailed description of the adverse event, in
this case, of neonatal seizures following maternal immunization.
The additional guidelines have been developed as guidance for
the collection of additional information to allow for a more com-prehensive understanding of neonatal seizures following maternal
immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants (including mothers
and infants, as appropriate), the following information should be
recorded:
(1) Date of report.
(2) Name and contact information of person reporting10 and/or
diagnosing the neonatal seizures as specified by country-
specific data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g., clinician, nurse, family member
[indicate relationship], other).
3.1.2. Vaccinee/Control
3.1.2.1. Demographics. For all cases and/or all study participants
(including mothers and infants as appropriate), the following infor-
mation should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For neonates: gestational age and birth weight, twin status.
3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants (including mothers and infants as appropriate),
the following information should be recorded:
(8) Past and current gynecological/obstetric history, medical
history, including hospitalizations, underlying diseases/dis-
orders, pre- immunization signs and symptoms including
identification of indicators for, or the absence of, a history
of allergy or other reactions to vaccines, vaccine components
or medications; food allergy; allergic rhinitis; eczema;
asthma. Any family history of seizure, neonatal/infant death
(sibling), or congenital/genetic conditions should be
recorded.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after maternal immunization
during pregnancy including prescription and non-prescrip-
tion medication as well as medication or treatment with
long half-life or long-term effect. (e.g. immunoglobulins,
blood transfusion and immunosuppressant).
(10) Maternal and infant immunization history (i.e. previous
immunizations and any adverse event following immuniza-
tion (AEFI), in particular occurrence of neonatal seizures
after a previous immunization).
3.1.3. Details of maternal and infant immunizations
For all cases and/or all study participants (including mothers
and infants as appropriate), the following information should be
recorded:
(11) Date and time of maternal and infant immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.) and number of dose
if part of a series of immunization s against the same
disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
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lar, intradermal, subcutaneous, and needle-free [including
type and size], and vaccine vial [used/open vial or new vial]
other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
Specifically document:
(17) Clinical description of signs and symptoms of neonatal sei-
zures, seizure type [79] and if there was medical confirma-
tion of the event (i.e. patient seen by appropriate health
care provider7, and/or testing performed).
(18) Date/time of onset11, first observation12 and diagnosis13,
duration and frequency of seizures (seizures/hour or seizur-
es/day), last seizure14 and final outcome15.
(19) Concurrent signs, symptoms, and diseases.
 Measurement/testing [89].
 Minimum EEG standards for cEEG are described in the
American Clinical Neurophysiology Society (ACNS)
guidelines [73,89].
 Minimum aEEG standards are described by de Vries and
Hellström-Westas (https://doi.org/10.1136/adc.2004.
062745) [90] and also in the American Clinical Neuro-
physiology Society (ACNS) guidelines (https://www.acns.
org/UserFiles/file/Guideline5-MinimumTechnicalStandards
forPediatricEEG_v1.pdf) [73].
 Details of EEG (Date, type, duration, quality)
 Results of electrolytes, blood gas, and serum glucose,
calcium, magnesium, bilirubin as well as complete blood
count and blood culture.
 Other investigations depend on clinical presentation, his-
tory and availability and may include lumbar puncture,
urine culture and toxicology (maternal toxicology
screen), screen for relevant congenital infections, meta-
bolic screen, and genetic testing.
 Ultrasound and neuroimaging (MRI or CT scan) if
available.(20) Treatment given for neonatal seizures, especially specify
drug(s) and dosing.
(21) Outcome15 at last observation. Persistence beyond the
neonatal period should be noted, ideally as late as 12–
18 months.
(22) Objective clinical evidence supporting classification of the
event as ‘‘serious” according to regulatory standards16.
(23) Maternal and infant exposures other than the maternal
immunization, including those 24 h before and after immu-
nization, and until delivery (e.g. food, medications, environ-
mental, etc.) considered potentially relevant to the reported
event.
3.1.5. Miscellaneous/general
The duration of surveillance for neonatal seizures should be
predefined based on the neonatal period (see case definition – up
to 28 days in term and up to 44 PMA in preterm infants). Events
with onset of seizures after this time are not considered neonatal
seizures although it is recognized that seizures may persist (onset
of epilepsy).
Biologic characteristics of the vaccine (e.g. live attenuated
versus inactivated component vaccines), biologic characteristics
of the vaccine-targeted disease, biologic characteristics of thevaccinee (e.g. nutrition, underlying disease like immune-depress-
ing illness) are not considered relevant for the choice of the dura-
tion of the surveillance for neonatal seizures.
(24) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(25) Methods of data collection should be consistent within and
between study groups, if applicable.
(26) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–23.
(27) Investigators of patients with neonatal seizures should pro-
vide guidance to reporters to optimize the quality and com-
pleteness of the information provided.
(28) Reports of neonatal seizures should be collected throughout
the study period regardless of the time elapsed between
maternal or infant immunization and the adverse event. If
this is not feasible due to the study design, the study periods
during which safety data are being collected should be
clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on neonatal seizures to allow for comparability
of data and are recommended as an addition to data analyzed for
the specific study question and setting.
(29) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories17Event meets case definition
Level 1: Criteria as specified in the neonatal seizures case
definition
Level 2: Criteria as specified in the neonatal seizures case
definition
Level 3: Criteria as specified in the neonatal seizures case
definition
Event does not meet case definition
Additional categories for analysis
Level 4: Reported neonatal seizures with insufficient
evidence to meet the case definition18
Level 5: Not a case of neonatal seizures19
(30) The interval between maternal immunization and reported
neonatal seizures is defined as the date/time of maternal
immunization to the date/time of onset11 of the first symp-
toms and/or signs consistent with the definition. Addition-
ally, the occurrence of neonatal seizures in relation to the
infant’s date of birth should be reported. If few cases are
reported, the specific time course could be analyzed for
each; for a large number of cases, data can be analyzed in
the increments based on trimester of maternal immuniza-
tion (see Table 6a).
Furthermore, it is useful to analyze time of onset of seizure
because some etiologies have a definite time of onset. For preterm
infants the age of onset is recorded as the corrected age and
chronological age (Table 6b).
Table 6
Reporting of time intervals. (a) Subjects with
neonatal seizures in relation to trimester of
maternal immunization. (b) Subjects with neona-
tal seizures in relation to date of birth (maternal
vaccination received any time during pregnancy).
Interval Number
(a)
First trimester
Second trimester
Third trimester
TOTAL
(b)
First 24 h of life (Day 1)
First 96 h of life (Day 1–4)
First week of life (Day 1–7)
Weeks 2–4 of life (Day 8–28)
TOTAL
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the date of onset of the first seizure consistent with the def-
inition and the last seizure14 and/or final outcome15. If sei-
zures persist beyond the neonatal period, this has to be
noted. Whatever start and end are used, they should be used
consistently within and across study groups.
(32) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(33) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases
are presented, the respective values or time course can be
presented individually.
(34) Data on neonatal seizures obtained from subjects born to
mothers receiving a vaccine should be compared with those
obtained from an appropriately selected and documented
control group(s) to assess background rates of neonatal sei-
zures in non-exposed populations and should be analyzed
by study arm and dose where possible, e.g. in prospective
clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on neonatal seizures following
maternal immunization to allow for comparability of data and
are recommended as an addition to data presented for the specific
study question and setting. Additionally, it is recommended to
refer to existing general guidelines for the presentation and publi-
cation of randomized controlled trials, systematic reviews, and
meta-analyses of observational studies in epidemiology (e.g. state-
ments of Consolidated Standards of Reporting Trials (CONSORT)
[91], of Improving the quality of reports of meta-analyses of ran-
domized controlled trials (QUORUM) [92], and of Meta-analysis
Of Observational Studies in Epidemiology (MOOSE) [93],
respectively).
(35) All reported events of neonatal seizures should be presented
according to the categories listed in guideline 29 or other
classification that is considered appropriate.
(36) Data on possible neonatal seizures events should be pre-
sented in accordance with data collection guidelines 1–23
and data analysis guidelines 29–34.(37) Terms to describe neonatal seizures such as ‘‘low-grade”,
‘‘mild”, ‘‘moderate”, ‘‘high”, ‘‘severe” or ‘‘significant” are
highly subjective, prone to wide interpretation, and should
be avoided, unless clearly defined.
(38) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
(39) Although denominator data are usually not readily avail-
able for immunization safety surveillance, attempts
should be made to identify approximate denominators.
The source of the denominator data should be reported,
and calculations of estimates be described (e.g. manufac-
turer data such as total doses distributed, reporting
through Ministry of Health, coverage/population-based
data, etc.). The incidence of cases in the study popula-
tion should be presented and clearly identified as such
in the text.
(40) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(41) Any publication of data on neonatal seizures after maternal
immunization should include a detailed description of the
methods used for data collection and analysis as possible.
It is essential to specify:
 The study design;
 The method, frequency and duration of monitoring for
neonatal seizures;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
 The search strategy in surveillance databases;
 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of maternal immunization was consid-
ered ‘‘day one” or ‘‘day zero” in the analysis;
 Whether the date of onset2 and/or the date of first obser-
vation3 and/or the date of diagnosis4 was used for analy-
sis; and
 Use of this case definition for neonatal seizures, in the
abstract or methods section of a publication20.Notes for guidelines
10If the reporting center is different from the vaccinating center,
appropriate and timely communication of the adverse event
should occur.
11The date and/or time of onset is defined as the time within the
neonatal period when the first sign or symptom indicative of
neonatal seizures occurred. This may only be possible to determine
in retrospect.
12The date and/or time of first observation of the first sign or
symptom indicative for neonatal seizures can be used if date/time
of onset is not known.
13The date of diagnosis of an episode is the day within the
neonatal period when the event met the case definition at any
level.
14The end of the occurrence of neonatal seizures is defined as
the time the subject no longer meets the case definition at the low-
est level of the definition.
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taneous resolution, therapeutic intervention, persistence of the
event, sequelae, death.
16An adverse event after immunization (AEFI) is defined as seri-
ous by international standards [94] if it meets one or more of the
following criteria: (1) it results in death, (2) is life-threatening,
(3) requires inpatient hospitalization or results in prolongation of
existing hospitalization, (4) results in persistent or significant dis-
ability/incapacity, (5) is a congenital anomaly/birth defect, (6) is a
medically important event or reaction.
17To determine the appropriate category, the user should first
establish, whether a reported event meets the criteria for the low-
est applicable level of diagnostic certainty, e.g. Level three. If the
lowest applicable level of diagnostic certainty of the definition is
met, and there is evidence that the criteria of the next higher level
of diagnostic certainty are met, the event should be classified in the
next category. This approach should be continued until the highest
level of diagnostic certainty for a given event could be determined.
If the lowest level of the case definition is not met, it should be
ruled out that any of the higher levels of diagnostic certainty are
met and the event should be classified in categories four or five.
The highest possible level of classification should be recorded for
each event.
18If the evidence available for an event is insufficient because
information is missing, such an event should be categorized as
‘‘Reported neonatal seizures with insufficient evidence to meet
the case definition”.
19An event does not meet the case definition if investigation
reveals a negative finding of a necessary criterion (necessary con-
dition) for diagnosis. Such an event should be rejected and classi-
fied as ‘‘Not a case of neonatal seizures”.
20Use of this document should preferably be referenced by
referring to the respective link on the Brighton Collaboration web-
site (http://www.brightoncollaboration.org).4. Disclaimer
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